For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Product revenue, net | 0 | - | ||
| Cost of sales | 0 | 5,953 | ||
| Cost of sales - inventory impairment and loss on firm purchase commitments | 0 | 118,680 | ||
| Acquired in-process research and development | 0 | 36,203 | ||
| Product revenue, net | - | 87,371 | ||
| Research and development | 90,404 | 104,084 | ||
| Selling, general and administrative | 62,887 | 114,331 | ||
| Restructuring expenses | 0 | 22,851 | ||
| Total operating expenses | 153,291 | 402,102 | ||
| Loss from operations | -153,291 | -314,731 | ||
| Interest income | 9,302 | 13,809 | ||
| Other expense, net | -700 | -1,214 | ||
| Total other income, net | 8,602 | 12,595 | ||
| Loss before income taxes | -144,689 | -302,136 | ||
| Provision (benefit) for income taxes | 46 | -393 | ||
| Net loss | -144,735 | -301,743 | ||
| Basic EPS | -1.53 | -4.43 | ||
| Diluted EPS | -1.53 | -4.43 | ||
| Basic Average Shares | 94,565,567 | 68,142,158 | ||
| Diluted Average Shares | 94,565,567 | 68,142,158 | ||
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)